Proteoglycans are biologically active components of the extracellular matrix consisting of a specific protein core post-translationally modified and covalently linked with linear glycosaminoglycans consisting of repeating disaccharides. The diversity in composition resulting from the various combinations of protein cores substituted with one or more glycosaminoglycan chains enables proteoglycans to interact with a host of different cell surface receptors, cytokines, growth factors, proteases, and other extracellular components. An emerging body of evidence indicates that secreted proteoglycans act as signaling molecules in addition to their canonical function in maintaining and regulating the architecture of various extracellular matrices. These interactions result in modulation of pivotal cellular processes
e.g. differentiation, proliferation, growth, adhesion, migration, autophagy, angiogenesis, and survival under developmental, physiological and pathological conditions. Therefore, proteoglycans are crucial regulators of cancer development, angiogenesis, fibrosis, inflammation, immunity, regenerative medicine, and diseases of the musculoskeletal and neuronal systems, and lung, renal and cardiovascular diseases.
The program of the 2020 Proteoglycans GRC entitled "Frontiers in Basic and Translational Proteoglycan Research to Improve Human Health" will highlight the latest findings in fundamental proteoglycan research addressing biosynthesis and catabolism as well as advances in the technologies used to study proteoglycans and glycosaminoglycans. A major focus of the 2020 Proteoglycans GRC is to underscore proteoglycans as therapeutic tools and targets. Thus, recent advances from preclinical studies using animal models to clinical studies targeting proteoglycans for treatment of various human diseases will lead to discussions among basic scientists and clinical researchers from academia, research institutes, and the pharmaceutical industry.
The conference will consist of nine sessions, on the topics listed below. The conference chair is currently developing their preliminary program, which will include the names of the invited speakers and discussion leaders for each of these sessions. The preliminary program will be available by
October 15, 2019. Please check back for updates.
Proteoglycan-Mediated Tissue Homeostasis
Proteoglycans and GAGs in Immuno-Oncology
Role of Proteoglycans in Development and Regenerative Medicine
New Technologies to Define the Role of PGs and GAGs in Health and Disease
Development of New Drugs Targeting Proteoglycans
Matrix-Targeted Glycan Therapeutics in Clinical Trials